Cambridge Investment Research Advisors’s Ginkgo Bioworks DNA Stock Holding History

Cambridge Investment Research Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-864	Closed	-$12K	–	3438
2024 Q2	$12K	Sell	864 -93	-10%	-$2.77K	﹤0.01%	3284
2024 Q1	$44K	Buy	957 +13	+1%	+$673	﹤0.01%	3223
2023 Q4	$64K	Buy	944 +44	+5%	+$2.69K	﹤0.01%	3085
2023 Q3	$65K	Buy	900 +12	+1%	+$959	﹤0.01%	3015
2023 Q2	$66K	Buy	888 +4	+0.5%	+$237	﹤0.01%	3060
2023 Q1	$47K	Buy	884 +53	+6%	+$3.36K	﹤0.01%	3039
2022 Q4	$56K	Buy	831 +481	+137%	+$44.2K	﹤0.01%	2969
2022 Q3	$44K	Buy	+350	New	+$41.7K	﹤0.01%	2951
2022 Q2	–	Sell	-265	Closed	-$43K	–	3091
2022 Q1	$43K	Buy	+265	New	+$51.6K	﹤0.01%	3085

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cambridge Investment Research Advisors's DNA Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 864 shares — an estimated $12K sold.

Cambridge Investment Research Advisors first reported a position in DNA in Q1 2022 and held it in 9 quarters. The position peaked at $66K in Q2 2023. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

Cambridge Investment Research Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
Cambridge Investment Research Advisors sold 864 Ginkgo Bioworks shares in Q3 2024, an estimated $12K.
Cambridge Investment Research Advisors first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 9 quarters.
Cambridge Investment Research Advisors's Ginkgo Bioworks position peaked at $66K in Q2 2023.
158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.